FDA Seeks Public Input to Support Ibogaine Research

FDA announced a request for public input on proposed approaches to early-phase trials of ibogaine drug products, relevant to sponsors developing these medicines. It seeks data and comments on dose selection, eligibility, care settings, safety monitoring, stopping rules and oversight.

Why it matters: FDA's request covers practical protocol elements, including cardiac and neurologic monitoring, informed consent and independent safety oversight.